

32-20494: Recombinant Human sTRAIL Receptor-1(Discontinued)

Alternative Name : soluble TRAIL Receptor-1, DR4, TNFRSF10A, Apo2

Description

Source: *E. coli* TRAIL Receptor-1/DR4 and TRAIL Receptor-2/DR5 belong to the TNFR superfamily of transmembrane proteins, and contain a cytoplasmic "death domain," which can activate the cell's apoptotic machinery. These receptors are activated by binding to either membrane-anchored or soluble TRAIL/Apo2L. The DR4 and DR5 receptors are both produced as type I transmembrane proteins, which contain an extracellular domain, a transmembrane domain, and a cytoplasmic domain. The recombinant soluble forms of DR4 and DR5 consist of the TNFR-homologous, cysteine-rich portion of their respective extracellular domains. Recombinant Human soluble TRAIL Receptor-1/DR4 is a 22.7 kDa protein (215 amino acid residues) consisting of the TNFR homologous, cysteine-rich portion of the extracellular domain.

Product Info

Amount : 10 µg / 50 µg

Purification : Purity: >= 98% by SDS-PAGE gel and HPLC analyses.

Content : This recombinant protein is supplied in lyophilized form.

Amino Acid : SGTGAAAATP SKVWGSSAGR IEPGGGGRGA LPTSMGQHGP SARARAGRAP GPRPAREASP
RLRVHKTFKF VVGVLLQVV PSSAATIKLH DQSIGTQQWE HSPLGELCPP GSHRSERPGA CNRCTEGVGY
TNASQQLFAC LPCTACKSDE EERSPCTTTR NTACQCKPGT FRNDNSAEMC RKCSTGCPRG
MVKVKDCTPW SDIECVHKES GNGHN

Application Note

Measured by its ability to inhibit apoptosis in LN-18 cells. The expected ED₅₀ for this effect is 0.4 -0.5 µg/ml.